Indications -- Psoriasis/Chronic Inflammation

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Indications -- Psoriasis/Chronic Inflammation

An SI Board Since February 2001

Posts	SubjectMarks	Bans
631	42	0

Emcee: scaram(o)uche	Type: Moderated

Introduction Compact

indication-specific file folder for psoriasis and/or chronic inflammation

first file entry..........

J Invest Dermatol 2001 Feb;116(2):319-329

Response of Psoriasis to Interleukin-10 is Associated with Suppression of
Cutaneous Type 1 Inflammation, Downregulation of the Epidermal
Interleukin-8/CXCR2 Pathway and Normalization of Keratinocyte
Maturation.

Reich K, Garbe C, Blaschke V, Maurer C, Middel P, Westphal G, Lippert U, Neumann
C

Department of Dermatology, Georg-August-University, Gottingen, Germany; Department of
Dermatology, Eberhard-Karls-University, Tubingen, Germany; Department of Pathology,
Georg-August-University, Gottingen, Germany; Department of Occupational Medicine,
Georg-August-University, Gottingen, Germany.

[Record supplied by publisher]

Psoriasis is a chronic inflammatory skin disease in which epidermal hyperplasia results from the
release of cytokines by infiltrating type 1 T cells. Up- regulation of endogenous interleukin-10
controls type 1 skin responses in animal models; however, interleukin-10 production is low in
psoriatic lesions. Consistent with an important role of interleukin-10 in psoriasis, we and
colleagues have recently demonstrated clinical efficacy of subcutaneous administration of
recombinant interleukin-10 to affected patients. Here, we studied the effects of interleukin-10 on
disease-related inflammatory pathways. Patients were treated with recombinant interleukin-10
over 6 wk in an open-label phase II clinical trial. Tissue was obtained before and after therapy
and examined by histology/immunohistochemistry, in situ hybridization, and quantitative real-time
reverse transcription-polymerase chain reaction. Ten of 14 patients showed a marked reduction
of the clinical disease activity. The clinical response was associated with a significant decrease of
cutaneous T cell infiltration and the lesional expression of type 1 cytokines interferon-gamma and
tumor necrosis factor-alpha. Interleukin-10 inhibited the epidermal interleukin-8 pathway by
downregulating the expression of interleukin-8, its receptor CXCR2, and its inducer
interleukin-17, and partially reversed the aberrant keratinocyte maturation defining psoriatic
epidermal pathology. Remarkably, there was evidence that genetic factors are involved in the
response to interleukin-10 as individual variations in the downregulation of tumor necrosis
factor-alpha were related to the presence of polymorphisms in the tumor necrosis factor-alpha
promoter. These data suggest that excessive production of type 1 cytokines in human skin
disease can be counter-regulated by the administration of recombinant interleukin-10. Genotypic
analysis may help to identify patients that will preferentially respond to interleukin-10 therapy.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
631	Oxidized phospholipids are proinflammatory and proatherogenic in hypercholestero	nigel bates	1	6/7/2018
630	Unpleasant side effect surprise for brodalumab: LONDON, May 26 (Reuters) - Astr	nigel bates	-	5/26/2015
629	best fit I can find..... Neuroimmunomodulation. 2013 Sep 24;21(1):1-7. [Epub a	scaram(o)uche	-	10/3/2013
628	Seen this? nature.com	scaram(o)uche	-	9/6/2013
627	About half a billion - but they're only worth a third of a Swedish Krone eac	nigel bates	-	9/6/2013
626	Must be a gatrillion shares outstanding?..... uk.finance.yahoo.com Novalon-der	scaram(o)uche	-	9/6/2013
625	STOCKHOLM, 5 September 2013 – The collaboration between Karo Bio AB and Pfizer I	nigel bates	-	9/6/2013
624	J Immunol. 2013 Aug 28. [Epub ahead of print] Cutting Edge: DNA Sensing via the	scaram(o)uche	-	8/30/2013
623	Niiiiiiiiiiiiiiiiice! Need to watch the various jak inhibitors. This was inter	scaram(o)uche	-	8/20/2013
622	Basel, July 8, 2013 - Novartis announced today top-line results from the head-to	nigel bates	-	8/20/2013
621	Drug Saf. 2013 Feb;36(2):135-44. doi: 10.1007/s40264-012-0013-7. Transplantatio	scaram(o)uche	-	8/4/2013
620	Dominant suppression of inflammation by glycan-hydrolyzed IgG pnas.org Kutty Sel	nigel bates	-	6/19/2013
619	PDE4 inhibition... Celgene International Sàrl, a subsidiary of Celgene Cor	nigel bates	-	6/14/2013
618	Nature. 2013 Jun 2. doi: 10.1038/nature12199. [Epub ahead of print] BACH2 repre	scaram(o)uche	-	6/6/2013
617	"Genomic responses in mouse models poorly mimic human inflammatory diseases	tuck	-	2/13/2013
616	ALLSCHWIL/BASEL, SWITZERLAND - 18 December 2012 - Actelion (SIX: ATLN) announced	nigel bates	-	12/18/2012
615	NDIANAPOLIS, Dec. 13, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) ann	nigel bates	-	12/14/2012
614	Free Radic Biol Med. 2012 Nov 1;54C:1-16. doi: 10.1016/j.freeradbiomed.2012.10.5	scaram(o)uche	-	12/4/2012
613	PLoS One. 2012;7(11):e49547. doi: 10.1371/journal.pone.0049547. Epub 2012 Nov 14	scaram(o)uche	-	11/21/2012
612	PLoS One. 2012;7(9):e44547. Epub 2012 Sep 6. SU5416, a VEGF Receptor Inhibitor	scaram(o)uche	-	10/13/2012
611	re. IL-17... secukinumab (AIN457, Novartis) is going to phase III for psoria	scaram(o)uche	-	10/5/2012
610	Cellceutix Informed by FDA That 505(b)(2) Application Would Be an Acceptable Ap	Savant	-	6/14/2012
609	One of biotech's first therapeutic projects, the magic CD4 epitope that tole	scaram(o)uche	-	8/20/2011
608	>>The evolution of drug resistance and the curious orthodoxy of aggressive	tuck	-	6/28/2011
607	ABBOTT PARK, Ill. and DREIEICH, Germany, June 21, 2011 /PRNewswire/ -- Abbott an	nigel bates	-	6/21/2011

Go to reply# or date (mm/dd/yy):